The careful gathering of women’s health science
Peptide therapy, decoded for women.
Editorial comparisons of peptide telehealth providers — credentials, pharmacy sourcing, pricing, states served — evaluated for women. Plus a free guide to bring to your first consult.
Every claim cited — studies, FDA documents, trial registries
Independent ratings · zero paid placements
Regulatory status dated on every entry
Compared. Six published criteria · zero paid placement. Editorial ratings come from the criteria — never from commercial relationships.
The 2026 moment
A different peptide conversation is finally possible.
April’s Category 2 revisions reshaped the regulated peptide landscape mid-stream. July’s PCAC review will move it again. This is the first year a careful editorial layer for women is both useful and necessary — and that’s the work.
Why women come here
We read the internet so you don’t have to.
PubMed, FDA filings, peer-reviewed journals, the long tail of women’s-health writing — aggregated, dated, and trimmed to what actually helps you make a decision. Four things you get here that a Google search won’t give you.
- 01
We did the reading
Hundreds of studies, FDA filings, and peer-reviewed papers — aggregated, dated, and organized around the question that brought you here (perimenopause, libido, skin, sleep, recovery, metabolic). You arrive informed, not exhausted from scrolling.
vs. Google: Google gives you ten generic articles ranked by SEO. None of them written for a woman.
- 02
Calibrated evidence vocabulary
Preclinical · limited clinical · multiple human studies · Phase 3 · FDA-approved. Each word means a specific thing, and we use them precisely on every entry.
vs. Google: Google says "studies show." We tell you whose body the study was in.
- 03
Regulatory clarity, post-April
April 2026 removed twelve peptides from FDA Category 2 — with a July 2026 PCAC review still scheduled. Both events flagged on every peptide page, with the FDA-approved exceptions separately marked.
vs. Google: Top Google hits are still telling you BPC-157 is banned. The picture changed in April.
- 04
Tools you can print
A twelve-question consult checklist with handwriting space. A provider scorecard. A one-page evidence chart. Designed for the consult itself, not just the read.
vs. Google: Google gives you information you read once and forget by Friday.
Start where you are
If your goal is X, the peptides worth knowing.
Six entry-points into the catalog — the peptides actually researched for each goal, with the FDA and evidence layer attached. Pick the one that brought you here.
Peptide in focus
Ipamorelin
Research-onlyHormone & GH-axisA selective growth-hormone secretagogue with a cleaner side-effect profile than older agents. Studied for body composition, sleep, and recovery. Compounding status under review in 2026.
Latest writing
New and recently updated.
- skin9 min
Peptides for Skin & Collagen: GHK-Cu and What It Does
GHK-Cu is one of the most-searched skincare peptides. Here's what the research shows for skin, collagen, and aging — and the difference between topical and injectable.
- hormone13 min
Peptides for Perimenopause: What the Research Actually Says
A grounded look at peptides discussed for perimenopause — GH-axis peptides, BPC-157, kisspeptin, collagen, GLP-1 — and where the evidence is strong versus preliminary, with the current 2026 regulatory and safety picture.
- libido10 min
PT-141 (Bremelanotide) for Women: Libido, Safety, and What to Know
PT-141 / Vyleesi is FDA-approved for low sexual desire in premenopausal women. Here's how it works, what the Phase 3 trials actually showed, and what to know about safety, off-label use, and access.
Editorially evaluated
Where to start your search.
Peptide-telehealth providers we've evaluated for women — based on credentials, pharmacy sourcing, pricing, and states served. Editorial ratings come from those criteria alone, never from commercial relationships.
Affiliate disclosure: Some links on this page are affiliate links. If you sign up with a provider after clicking, Anthivera may receive a referral fee at no additional cost to you. Editorial ratings reflect our judgment, not commercial relationships. Read the full disclosure.
Solace MD
4.6/5Higher price band, faster shipping, more personal care — the right fit if cost isn't the primary constraint.
- Price
- $110–$340/mo
- States
- 7 served
Read the reviewVisit siteEvergreen Women's Health
4.5/5Strongest fit for perimenopausal women seeking continuity of care — pairs hormone testing with peptide protocols.
- Price
- $89–$249/mo
- States
- 10 served
Read the reviewVisit siteNorthstar Peptide Co.
4.2/5Specialty: recovery and skin peptides. Less hormone-focused than competitors, but a tighter, more specialized catalog.
- Price
- $75–$220/mo
- States
- 8 served
Read the reviewVisit siteCanopy Telehealth Clinic
4.0/5Broad catalog and broad geographic reach; longer intake process but thorough lab work.
- Price
- $99–$299/mo
- States
- 12 served
Read the reviewVisit site
Join Anthivera Insider.
One careful, research-backed email a week on peptide therapy for women. No hype. Unsubscribe anytime.
The middle is harder — reading the trials, dating the regulatory status, saying “limited” out loud when the data is limited. — The Anthivera editors